Action 4123 CENTER LABORATORIES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Center Laboratories, Inc.

Actions

4123

TW0004123005

Cours en clôture Taipei Exchange
Autres places de cotation
 00:00:00 30/04/2024 		Varia. 5j. Varia. 1 janv.
43,45 TWD -0,34 % Graphique intraday de Center Laboratories, Inc. +2,24 % -1,92 %
19/03 Center Laboratories, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI
06/02 Center Laboratories, Inc. annonce que Wang, Su-Chi occupe simultanément les postes de Chief Investment Officer et de Chief Operating Officer CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Center Laboratories, Inc. cancelled the transaction announced on June 20, 2023
Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mycenax Biotech Inc. announced that it expects to receive funding from Center Laboratories, Inc., JCR Pharmaceuticals Co., Ltd., Taiwan BioVenture Company, Jason Technologies Ltd
Center Laboratories, Inc. Announces Wang, Su-Chi Holds Concurrent Position as Chief Investment Officer and Chief Operating Officer
Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2022, Payable on October 13, 2023
Center Laboratories, Inc. announced a financing transaction
Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Center Laboratories, Inc. Proposes Cash Dividend for the Period from January 1, 2022 to December 31, 2022
Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Center Laboratories, Inc. Announces Executive Appointments
Center Laboratories, Inc. Announces Management Changes
Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Bao Pharma announced that it has received $100 million in funding from Shenzhen Oriental Fortune Capital Co., Ltd., Finnova Capital, Haitong Innovation Private Fund Management Co., Ltd., Shanghai Sun Rock Capital Management Co., Ltd., Center Laboratories, Inc.
Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Center Laboratories : To announce the ex-rights and dividend record date and the closure period for the conversion of CB4 and CB5
Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2021
Center Laboratories : Amendment on the Company's 2021 Annual Report
Center Laboratories : Announcement on the change of internal audit officer
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 4123
  4. Actualités Center Laboratories, Inc.
  5. Autres langues